Perrigo Analyst Ratings
BenzingaApr 12 11:49 ET
Perrigo's Game-Changing Opill Gains Groundbreaking CVS Coverage: A Buy Rating Endorsement
TipRanksApr 8 07:25 ET
Perrigo Analyst Ratings
BenzingaApr 8 07:15 ET
Piper Sandler Remains a Buy on Perrigo Company (PRGO)
TipRanksApr 5 06:47 ET
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Seeking AlphaMar 8 10:21 ET
JP Morgan Maintains Overweight on Perrigo, Lowers Price Target to $41
BenzingaFeb 28 09:57 ET
Perrigo Analyst Ratings
BenzingaFeb 28 09:56 ET
Piper Sandler Remains a Buy on Perrigo Company (PRGO)
TipRanksJan 12 07:37 ET
Piper Sandler Issues a Buy Rating on Perrigo Company (PRGO)
TipRanksJan 3 07:51 ET
Piper Sandler Initiates Coverage On Perrigo With Overweight Rating, Announces Price Target of $37
BenzingaNov 17, 2023 05:07 ET
Perrigo Analyst Ratings
BenzingaNov 17, 2023 05:05 ET
Perrigo Company's Stock: A Buy Rating Amid Margin Improvements and Potential Upside From Opill Launch
TipRanksNov 8, 2023 07:43 ET
JP Morgan Maintains Overweight on Perrigo, Raises Price Target to $48
BenzingaAug 9, 2023 12:37 ET
Perrigo Analyst Ratings
BenzingaAug 9, 2023 12:36 ET
Canaccord Genuity Initiates Coverage On Perrigo With Buy Rating, Announces Price Target of $49
BenzingaMar 7, 2023 08:43 ET
Raymond James Adjusts Perrigo Price Target to $43 From $42, Maintains Outperform Rating
MT NewswiresMar 6, 2023 08:42 ET
Raymond James Reaffirms Their Buy Rating on Perrigo Company (PRGO)
TipRanksMar 5, 2023 07:51 ET
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO), FibroGen (FGEN) and Disc Medicine (IRON)
TipRanksFeb 28, 2023 06:46 ET
Raymond James Adjusts Price Target on Perrigo Company to $42 From $48, Maintains Outperform Rating
MT NewswiresNov 9, 2022 10:39 ET
Perrigo Analyst Ratings
Benzinga Analyst RatingsNov 9, 2022 07:38 ET
No Data
No Data